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ABSTRACT
Retinoid X receptor α (RXRα) and its N-terminally trun-
cated version tRXRα play important roles in tumorige-
nesis, while some RXRα ligands possess potent anti-
cancer activities by targeting and modulating the
tumorigenic effects of RXRα and tRXRα. Here we
describe NSC-640358 (N-6), a thiazolyl-pyrazole derived
compound, acts as a selective RXRα ligand to promote
TNFα-mediated apoptosis of cancer cell. N-6 binds to
RXRα and inhibits the transactivation of RXRα homod-
imer and RXRα/TR3 heterodimer. Using mutational
analysis and computational study, we determine that
Arg316 in RXRα, essential for 9-cis-retinoic acid binding
and activating RXRα transactivation, is not required for
antagonist effects of N-6, whereas Trp305 and Phe313
are crucial for N-6 binding to RXRα by forming extra π–π
stacking interactions with N-6, indicating a distinct
RXRα binding mode of N-6. N-6 inhibits TR3-stimulated
transactivation of Gal4-DBD-RXRα-LBD by binding to
the ligand binding pocket of RXRα-LBD, suggesting a
strategy to regulate TR3 activity indirectly by using
small molecules to target its interacting partner RXRα.
For its physiological activities, we show that N-6
strongly inhibits tumor necrosis factor α (TNFα)-induced
AKT activation and stimulates TNFα-mediated apoptosis
in cancer cells in an RXRα/tRXRα dependent manner.
The inhibition of TNFα-induced tRXRα/p85α complex
formation by N-6 implies that N-6 targets tRXRα to
inhibit TNFα-induced AKT activation and to induce
cancer cell apoptosis. Together, our data illustrate a new
RXRα ligand with a unique RXRα binding mode and the
abilities to regulate TR3 activity indirectly and to induce
TNFα-mediated cancer cell apoptosis by targeting
RXRα/tRXRα.
KEYWORDS NSC-640358, ligand, RXRα, tRXRα,
TNFα, apoptosis
INTRODUCTION
Retinoid X receptor α (RXRα), a unique member of the
nuclear receptor superfamily, plays a pivotal role in diverse
biological and physiological processes, including cell growth,
differentiation, apoptosis, and homeostasis (Szanto et al.,
2004; Evans and Mangelsdorf, 2014). RXRα has the typical
structure of nuclear receptor, including an N-terminal region,
a central DNA-binding domain (DBD), and a C-terminal
ligand-binding domain (LBD) (de Lera et al., 2007). The
unique property of RXRα among nuclear receptors lies in its
ability to form heterodimers with many other nuclear recep-
tors such as retinoic acid receptors (RARs) and peroxisome
proliferator-activated receptors (PPARs) (Lefebvre et al.,
2010; Evans and Mangelsdorf, 2014). Like other nuclear
receptors, RXRα has important genomic functions mainly
through its binding to responding DNA elements to regulate
target gene transcription (Tang and Gudas, 2011; Evans andFan Chen, Jiebo Chen and Jiacheng Lin have contributed equally to
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Mangelsdorf, 2014). Recently, accumulating evidence indi-
cate that RXRα also resides in the cytoplasm to exhibit its
non-genomic actions (Katagiri et al., 2000; Cao et al., 2004;
Ghose et al., 2004; Zimmerman et al., 2006). For example,
under certain stimuli, RXRα migrates from nucleus to cyto-
plasm with nerve growth factor IB (NGFIB, also known as
Nur77 and TR3) to induce cell apoptosis by binding to Bcl-2
and converting Bcl-2 from an anti-apoptotic to a pro-apop-
totic molecule (Li et al., 2000a; Cao et al., 2004; Lin et al.,
2004).
Dysfunctions of RXRα are implicated in the initiation and
development of a variety of diseases including cancer
(Shulman and Mangelsdorf, 2005; Tang and Gudas, 2011).
For examples, targeted disruption of RXRα gene leads to
skin abnormalities and prostatic preneoplastic lesions (Li
et al., 2000b; Huang et al., 2002), while abnormal phos-
phorylation of RXRα is associated with the progresses of
colon cancer and liver cancer (Matsushima-Nishiwaki et al.,
2001). The expression level of RXRα is often found reduced
in cancer cells and tissues, implying the association of the
less RXRα expression and carcinogenesis (Jiang et al.,
1999; Lotan et al., 2000; Takiyama et al., 2004). A number of
studies have shown that proteolytic cleavage of RXRα is one
of the mechanisms for lower expression of RXRα in cancer
cells (Nagaya et al., 1998; Nomura et al., 1999; Casas et al.,
2003). Recently, we showed that calpain II cleaves RXRα to
produce a truncated RXRα–tRXRα in cancer cells (Gao
et al., 2013). Different from full-length RXRα, tRXRα is able
to reside in the cytoplasm and interact with p85α, the subunit
of phophoinositide 3-kinase (PI3K), which leads to the
enhanced TNFα-induced AKT activation (Zhou et al., 2010;
Wang et al., 2013). tRXRα-mediated activation of the TNFα/
PI3K/AKT pathway signiﬁcantly promotes cancer cell growth
both in vitro and in vivo (Zhou et al., 2010; Wang et al.,
2013), providing a potential approach to inhibit cancer cell
growth by targeting tRXRα with small molecules to inhibit
TNFα/PI3K/AKT survival pathway.
The functions of nuclear receptors are tightly and deli-
cately regulated by their cognate ligands (Gronemeyer et al.,
2004). A number of natural and synthetic compounds have
been identiﬁed as RXRα selective ligands (Altucci et al.,
2007; de Lera et al., 2007; Dawson and Xia, 2012). In
general, the chemical structures of RXRα ligands, such as
9-cis-retinoic acid (9-cis-RA) and LG100754, contain an
acidic moiety and a large hydrophobic moiety. The acidic
moiety is able to form salt bridges with Arg316 residue in
RXRα ligand binding pocket (LBP), which contributes
immensely to ligand-receptor interaction (Altucci et al., 2007;
Dawson and Xia, 2012). Comparison of RXRα apo (unli-
ganded) and holo (liganded) crystal structures reveals a
ligand-induced conformational change of RXRα, which sig-
niﬁcantly affects the interactions of RXRα with other proteins
such as co-activators and co-repressors (de Lera et al.,
2007). Although binding to the same LBP, different ligands
induce distinct functions of RXRα, which is due to the distinct
conformational changes of RXRα induced by different
ligands (Altucci et al., 2007; de Lera et al., 2007; Perez et al.,
2012). TR3 is an orphan nuclear receptor which can form
heterodimer with RXRα (Moll et al., 2006). Crystal studies
have shown that the LBD of TR3 lacks a typical hydrophobic
pocket for accommodating ligands (Wang et al., 2003).
However, TR3 is able to recruit co-activator for transactiva-
tion independent of ligand binding (Wansa et al., 2002),
reﬂecting its active unliganded conformation resembling
other agonist-activated nuclear receptors.
In this study, we show that NSC-640358 (N-6) is a
selective RXRα antagonist with a unique RXRα binding
mode. Through binding to RXRα, N-6 inhibits RXRα trans-
activation and RXRα-mediated transcriptional activity of
TR3. Moreover, N-6 inhibits tumor necrosis factor α (TNFα)-
induced AKT activation and enhances TNFα-mediated can-
cer cell apoptosis in an RXRα/tRXRα dependent manner.
RESULTS
N-6 binds to RXRα
We used Q-MOL molecular modeling package to perform a
virtual screening of a compound library for RXRα ligands, and
found that NSC-640358 ((NZ)-N-[1-[2-(3,5-diphenylpyrazol-
1-yl)-4-methyl-1,3-thiazol-5-yl]ethylidene]droxylamine, N-6), a
thiazolyl-pyrazole derived compound, was a potential RXRα
ligand (Fig. 1A). The interaction of N-6 and RXRα was ﬁrst
examined by ligand competition binding assay. As a positive
control, unlabeled 9-cis-RA displaced [3H]-labeled 9-cis-RA
for binding to RXRα-LBD protein in a dose-dependent manner
(Fig. 1B). Similarly, N-6 dose-dependently competed with
[3H]-labeled 9-cis-RA for binding to RXRα-LBD protein with an
IC50 at 11.3 μmol/L (Fig. 1B), suggesting the direct binding of
N-6 to RXRα. Then we performed surface plasmon reso-
nance (SPR) technology-based experiment to conﬁrm their
physical binding. As shown in Fig. 1C, N-6 dose-dependently
binds to RXRα-LBD with a Kd value of 15.7 μmol/L. Further-
more, our ﬂuorescence ligand binding assay showed that
RXRα-LBD protein potently enhanced the ﬂuorescence
intensity of N-6 (Fig. 1D). Together, these results demonstrate
that N-6 is able to bind to RXRα directly.
N-6 selectively inhibits RXRα transactivation
To examine whether N-6 regulated RXRα transactivation, a
reporter gene containing RXRα homodimer-responsive ele-
ments, (TREpal)2-tk-CAT (Dawson et al., 2001), was trans-
fected with a RXRα expression vector into CV-1 cells that
lack detectable levels of endogenous RXRα (Zhang et al.,
1992a, b). Treatment of cells with 9-cis-RA potently induced
the transactivation of RXRα homodimer, which was dose-
dependently inhibited by N-6 (Fig. 2A). In contrast, N-6 failed
to inhibit 9-cis-RA-induced transactivation of RARγ homod-
imer or the ligand-independent transactivation of Nur77
(Fig. 2B and 2C) (Kolluri et al., 2003). Thus, N-6 selectively
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inhibits RXRα transactivation, which was further conﬁrmed
by our mammalian one-hybrid technology-based assay. N-6
strongly inhibited 9-cis-RA-induced Gal4-DBD-RXRα-LBD
transactivation but not the other chimeric nuclear receptors,
such as RARγ, TR3, GR, LXRα and PPARγ (Fig. 2D–I). We
next examined the effects of N-6 on the transcriptional
activity of RXRα/TR3 heterodimer. To this end, CV-1 cells
were transfected with RXRα and TR3 expression vectors
together with βRARE-tk-CAT reporter. 9-cis-RA-induced
transactivation of RXRα/TR3 heterodimer was strongly
inhibited by N-6 (Fig. 2J). It is known that the binding of 9-cis-
RA induces RXRα conformational change, leading to co-
activator recruitment. We then examined whether N-6
inhibited 9-cis-RA-induced co-activator recruitment. As
shown in Fig. 2K, N-6 dose-dependently inhibited 9-cis-RA-
induced interaction of co-activator and RXRα-LBD with an
IC50 at 32.9 μmol/L. Taken together, these ﬁndings indicate
that N-6 is a selective antagonist of RXRα.
N-6 regulates TR3 activity by binding to RXRα
In the absence of RXRα agonists, the fusion protein Gal4-
DBD-RXRα-LBD only exhibited basal transactivation. How-
ever, transfection of TR3 remarkably enhanced its transac-
tivation (Fig. 3A). The salt bridges formed by Glu453/456 in
helix 12 and Arg302 in helix 4 are essential for maintaining
co-activator binding site in RXRα (Egea et al., 2000; Egea
et al., 2002). The fusion protein Gal4-DBD-RXRα-LBD/E453/
456A, with Ala substituted with Glu, completely lost trans-
activation ability in response to 9-cis-RA and CD3254
(Fig. 3B). However, TR3 was still able to stimulate the
reporter gene activity together with Gal4-DBD-RXRα-LBD/
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Figure 1. N-6 binds to RXRα. (A) Structure of NSC-640358 (N-6). (B) RXRα-LBD protein was incubated with [3H]9-cis-RA in the
presence or absence of unlabeled 9-cis-RA or N-6. Bound [3H]9-cis-RA was quantitated by liquid scintillation counting. (C) Gradient
concentrations of N-6 were injected through ﬂow cells immobilized with RXRα-LBD. The kinetic proﬁles are shown and the
dissociation constant (Kd) of the N-6/RXRα-LBD complex was calculated to be 15.755 × 10
−6 mol/L. (D) RXRα-LBD protein enhanced
ﬂuorescent intensity of N-6 (ex 278 nm, em 338 nm, cutoff 325 nm, delay 50 μs, integration 450 μs). One of three similar experiments
is shown.
RESEARCH ARTICLE Fan Chen et al.









E453/456A (Fig. 3C). Sequence analysis indicated there
were no cognate TR3 binding sites in the G5 reporter vector.
Thus, the ability of TR3 to induce the transactivation was due
to the interaction of Gal4-DBD-RXRα-LBD with TR3 and TR3
ligand-independent transactivation. No matter what above
fusion proteins were used, TR3-induced transactivation was
potently inhibited by N-6 (Fig. 3D). However, in the case of
Gal4-DBD-RXRα-LBD/C432Y with disrupted RXRα-LBP due
to the substitution of Cys with Tyr, N-6 completely lost its
activity (Fig. 3D), suggesting the necessity of the binding of
N-6 to RXRα-LBD. Similar results were observed when
RXRα antagonist UVI3003 was examined (Fig. 3D). Thus,
N-6 and UVI3003 bind to RXRα to indirectly inhibit TR3
transactivation. One possible mechanism by which N-6
inhibited TR3 transactivation was the disruption of the
interactions of TR3 with the fusion proteins, which was
analyzed by our co-immunoprecipitation experiments. As
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Figure 2. N-6 is a selective antagonist of RXRα. (A–C) CV-1 cells were cotransfected with (TREpal)2-tk-CATand pCMV-Myc-RXRα
(A), (TREpal)2-tk-CATand pCMV-Myc-RARγ (B), or NurRE-tk-CATand pCMV-Myc-Nur77 (C). Cells were treated with N-6 (10 μmol/L)
and 9-cis-RA (10−7 mol/L) for 18 h. CAT activities were measured and normalized to β-galactosidase activities (*P < 0.05). (D–I)
MCF-7 cells were cotransfected with pG5-Gaussia-Dura and pBIND-RXRαLBD (D), pBIND-RARγLBD (E), pBIND-TR3 (F), pBIND-
GRLBD (G), pBIND-LXRαLBD (H), or pBIND-PPARγLBD (I). Cells were treated with N-6 (10 μmol/L) in the presence or absence of
0.1 μmol/L 9-cis-RA (D and E), 1 μmol/L Dexamethasone (Dex) (G), 1 μmol/L T0901317 (T09) (H), or 1 μmol/L Rosiglitazone (Ros)
(I) for 18 h. Reporter activities were measured and normalized (*P < 0.05). (J) CV-1 cells transfected with βRARE-tk-CAT, RXRα and
TR3 expression vectors were treated with N-6 (10 μmol/L) in the presence or absence of 9-cis-RA (10−7 mol/L) for 18 h. CATactivities
were measured and normalized to β-galactosidase activities (*P < 0.05). (K) GST-RXRα-LBD was incubated with different
concentrations of N-6 in the presence of 9-cis-RA (10−8 mol/L) for 2 h. FRETsignals were measured and normalized. The IC50 of N-6
was calculated to be 3.29 × 10−5 mol/L. One of three similar experiments is shown. Data shown are mean ± SD.
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proteins, as evidenced by their co-precipitation. Neither N-6
nor UVI3003 affected their interactions (Fig. 3E). GAL4-
DBD-TR3-LBD had low, if there was, transactivation activity,
which was due to the loss of the N-terminal TR3 (Wansa
et al., 2002). When both GAL4-DBD-TR3-LBD and p16-
ACT-RXRα fusion proteins existed, a dramatic induction of
the reporter gene activity was observed, which reﬂected a
typical mammalian two-hybrid assay to show the interaction
of RXRα and TR3-LBD. In this context, neither N-6 nor
UVI3003 was able to inhibit the induced transactivation
(Fig. 3F), which also demonstrated the inability of N-6 and
UVI3003 for blocking the interaction of TR3 and RXRα.
Therefore, it is not through the disruption of the interaction of
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Figure 3. N-6 inhibits TR3 transcriptional activity by binding to RXRα. (A–D, and F) MCF-7 cells cotransfected with pG5-
Gaussia-Dura reporter vector and the indicated expression vectors were treated with or without N-6 (10 μmol/L), UVI3003 (1 μmol/L),
and 9-cis-RA (10−7 mol/L) for 18 h. Reporter activities were measured and normalized. Data shown are mean ± SD (*P < 0.05).
(E) HEK293T cells cotransfected with pCMV-Myc-TR3 and pBIND-RXRα-LBD expression vectors were treated with UVI3003
(1 μmol/L) or N-6 (10 μmol/L) for 18 h. Cell lysate were analyzed for heterodimerization of Nur77 and Gal4-DBD-RXRα-LBD by co-
immunoprecipitation with anti-myc antibody. One of three similar experiments is shown.
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N-6 binds to RXRα in a distinct mode
Unlike many natural and synthetic RXRα ligands, N-6 lacks a
carboxylate moiety known to form salt bridges with Arg316 in
RXRα-LBP. To examine the requirement of Arg316 for N-6, it
was replaced with Glutamic acid, and the resulting mutant
Gal4-DBD-RXRαLBD/R316E was evaluated for its transac-
tivation regulated by N-6. As shown in Fig. 4A, CD3254 was
able to stimulate the transactivation of the mutant. Similar to
RXRα-LBD, CD3254-induced transactivation of RXRα-LBD/
R316E was potently inhibited by N-6 (Fig. 4A), implying that
Arg316 was not required for N-6 binding to RXRα. We then
used computer-aided and docking-based techniques to
analyze the binding mode of N-6. In light of the antagonist
activity of N-6 and a large degree of structural overlapping
between N-6 and LG100754 (Fig. 4B), an antagonist of
RARα/RXRα heterodimer (Sato et al., 2010), it was rea-
sonable that the model of RXRα under its antagonist con-
formation should be used for the docking of N-6. In fact, our
docking study showed that N-6 was well accommodated into
the LBP of RXRα with an antagonist conformation (Fig. 4C).
Unlike LG100754, N-6 did not form ionic bonds (2.3 Å and
1.5 Å for LG100754) with Arg316. However, N-6 possesses
two aromatic rings that could establish extra π-π stacking
interactions with Phe313 and Trp305 (Fig. 4C). The essential
role of Phe313 and Trp305 in N-6 binding was conﬁrmed by
our SPR assays, showing that N-6 had much lower binding
afﬁnity to two RXRα-LBD point mutants with Ala substitution
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Figure 4. Arg316 is not required for N-6 binding to RXRα. (A) MCF-7 cells cotransfected with pG5-Gaussia-Dura reporter vector
and pBIND-RXRα-LBD or pBIND-RXRα-LBD/R316E expression vectors were treated with or without N-6 (10 μmol/L) in the presence
or absence of CD3254 (10−7 mol/L) for 18 h. Reporter activities were measured and normalized. Data shown are mean ± SD
(*P < 0.05). (B) Comparison of the docked conformation of N-6 (gray) with the crystal structure of LG100754 (green). (C) N-6 was
docked into the LBP of the co-crystal structure of LG100754 and RXRα-LBD (PDB 3A9E). Salt bridges are shown as dotted yellow
lines, and residues interacting with N-6 are shown in magenta. (D–E) Gradient concentrations of N-6 were injected through ﬂow cells
immobilized with RXRα-LBD/Trp305Ala (D) and RXRα-LBD/Phe313Ala (E), respectively. The kinetic proﬁles are shown and the
dissociation constants (Kd) of the N-6/RXRα-LBD complex were calculated to be 1.0 × 10
−3 mol/L (D) and more than 1.0 × 10−2 mol/L
(E). (F) RXRα-LBD proteins (2 mg/mL) was incubated with DMSO, 10 μmol/L 9-cis-RA, 25 μmol/L N-6 or 50 μmol/L N-6 for 3 h, and
proteins were separated by 8% nondenaturing PAGE followed by Commassie Blue staining.
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docking study showed that two hydrophobic residues Ile324
and Leu326 could produce additional hydrophobic interac-
tions with N-6 (Fig. 4C). Ligand binding often leads to the
conformational change of RXRα protein, which was investi-
gated for N-6 by our native gel electrophoresis assay. Con-
sistent with previous reports, 9-cis-RA strongly induced the
homodimeric formation of RXRα-LBD protein. However, N-6
dose-dependently induced the conformational changes of
RXRα-LBD dimer, indicated by the pattern changes of the
dimer bands (Fig. 4F). Taken together, our data indicate that
N-6 has a distinct binding model comparing with classic
RXRα ligands.
N-6 inhibits TNFα-induced AKT activation in an RXRα/
tRXRα dependent manner
It has been reported that RXRα antagonist K-80003 inhibits
TNFα-induced AKT activation in a tRXRα-dependent path-
way (Zhou et al., 2010). Here we examined whether N-6 had
a similar function. Figure 5A showed that N-6 signiﬁcantly
inhibited TNFα-induced AKT activation in HCT116 cells,
revealed by its suppression of the expression of phosphor-
AKT but not total AKT (Fig. 5A). Similar results were
obtained in A549 cells (Fig. 5B). We then determined the
requirement of RXRα/tRXRα for the inhibition of AKT acti-
vation by N-6. Transfection of RXRα siRNA in A549 cells,
which reduced both the full-length RXRα and tRXRα
expression, abolished the inhibitory effect of N-6 on TNFα-
induced AKT activation (Fig. 5B). Thus, the expression of
RXRα/tRXRα is essential for AKT inhibition by N-6. We have
reported that K-80003 inhibited AKT activation by blocking
the TNFα-induced interaction of tRXRα and p85α (Zhou
et al., 2010). We then investigated whether N-6 had the
similar action. Two anti-RXRα antibodies, ΔN197 and D20,
were used in the co-immunoprecipitation assay, of which
ΔN197 but not D20 could recognize both RXRα and tRXRα
(Zhou et al., 2010). Consistent with our previous reports
(Zhou et al., 2010), TNFα strongly induced the interaction of
tRXRα but not RXRα with p85α showed by our co-im-
munoprecipitation experiment (Fig. 5C). However, when
cells were treated with N-6 together with TNFα, the interac-
tion of tRXRα and p85α promoted by TNFα was completely
blocked (Fig. 5C and 5D). Thus, the inhibitory effect of N-6
on TNFα-induced AKT activation might rely on its disruption
of the interaction of tRXRα with p85α.
N-6 induces RXRα/tRXRα-dependent apoptosis
of cancer cell
The ability of N-6 to inhibit AKT activation prompted us to
examine the effect of N-6 on the survival of cancer cells by
colonogenic survival assay. Treatment of cells with N-6 sig-
niﬁcantly inhibited colony formation of HeLa cells, which was
dramatically enhanced by TNFα (Fig. 6A). The inhibition of
TNFα-induced AKT activation often leads to the activation of
TNFα-mediated apoptosis (Zhou et al., 2010; Wang et al.,
2013). Indeed, the combination of TNFα and N-6 synergis-
tically induced PARP cleavage in HCT116 cells (Fig. 6B).
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Figure 5. N-6 inhibits TNFα-induced AKT activation in a tRXRα-dependent manner. (A) HCT116 cells were pretreated with N-6
(10 μmol/L) for 2 h in serum free medium before being exposed to TNFα (10 ng/mL) for an additional 30 min. Lysates prepared were
analyzed by Western blotting for AKT activation. (B) A549 cells transfected with RXRα siRNA or control siRNA for 48 h were treated
with N-6 (10 μmol/L) for 2 h in serum free medium before being exposed to TNFα (10 ng/mL) for an additional 30 min. Lysates
prepared were analyzed by Western blotting for AKT activation. (C and D) H292 cells (C) or A549 cells (D) pretreated with N-6
(10 μmol/L) for 2 h in serum free medium before being exposed to TNFα (10 ng/mL) for an additional 30 min were analyzed for p85α/
tRXRα interaction by co-immunoprecipitation assay using anti-RXRα antibodies of D20 or ΔN197. Immunoprecipitates were analyzed
by Western blotting for the presence of p85α and tRXRα. One of three similar experiments is shown.
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The synergistic induction of PARP cleavage was TNFα-
concentration dependent in MCF-7 cells (Fig. 6C). Further-
more, our TUNEL staining assay conﬁrmed the synergistic
pro-apoptosis of the combination (Fig. 6D). We then deter-
mined the role of RXRα/tRXRα in apoptosis induction of the
combination using knocking down approach. Compared to
control siRNA, RXRα siRNA impaired the ability of the
combination of N-6 and TNFα for the induction of PARP
cleavage (Fig. 6E). Accompanying with PARP cleavage, the
combined treatment also induced caspase-8 activation,
which was also inhibited by the suppression of RXRα/tRXRα
expression (Fig. 6E). Thus, RXRα/tRXRα is involved in the
apoptotic induction of the combination of N-6 and TNFα.
DISCUSSION
RXRα is a promising drug target for cancer therapy, as it has
an inner LBP to accommodate “drug-like” small molecule
modulators (Altucci et al., 2007; de Lera et al., 2007). In
addition, dysfunctions or abnormal expressions of RXRα are
implicated in tumor development (Tang and Gudas, 2011;
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Figure 6. Combination of TNFα and N-6 induces cancer cell apoptosis in an RXRα/tRXRα-dependent manner. (A) HeLa cells
grown in 6-well plates were treated with or without N-6 (5 μmol/L) and TNFα (10 ng/mL) for 3 days. Colonies were stained with 0.1%
crystal violet and counted. (B and C) HCT116 and MCF-7 cells were treated with or without N-6 (10 μmol/L) and TNFα (10 ng/ mL) for
15 h in serum free medium. Cell lysates prepared were analyzed by Western blotting for PARP cleavage. (D) MCF-7 cells grown in
24-well plates were treated with or without N-6 (10 μmol/L) and/or TNFα (10 μg/mL) for 3 days. Apoptotic cells were detected by
TUNEL staining and counted. (E) HCT116 cells transfected with RXRα siRNA or control siRNA for 48 h were treated with or without
N-6 (10 μmol/L) and TNFα (10 ng/mL) for 15 h. Cell lysates prepared were analyzed by Western blotting for PARP and caspase-8
cleavage. One of three similar experiments is shown.
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antagonist K-80003 exhibits striking anti-cancer effects by
inhibiting the cytoplasmic activation of PI3K/AKT by tRXRα
(Zhou et al., 2010). Here, we present a new RXRα ligand
with a distinct structure and an RXRα/tRXRα-dependent
induction of cancer cell apoptosis with TNFα.
The structure of N-6 is very different from known RXRα
ligands such as 9-cis-RA and LG100754. However, it bound
to RXRα with a unique mode and acted as an RXRα
antagonist (Figs. 1, 2 and 4). The holo-crystal structure of
9-cis-RA and RXRα-LBD indicates that the salt bridge
formed via Arg316 at the end of the L-shaped LBP and the
carboxylate group of 9-cis-RA is crucial for 9-cis-RA binding
to RXRα (Egea et al., 2000; Egea et al., 2002; Sato et al.,
2010). N-6 lacks such a carboxylate moiety, and therefore it
should not require Arg316 for binding, which was veriﬁed by
our mammalian one-hybrid assay showing that the mutation
of Arg316 did not affect the inhibition of RXRα transactivation
by N-6 (Fig. 4A). Recently, several compounds without car-
boxylate moiety such as CF31, Danthron, Magnolol, and
Bigelovin were reported to bind to RXRα (Zhang et al.,
2011a; Zhang et al., 2011b; Zhang et al., 2011c; Wang et al.,
2013). Therefore, salt bridges are not necessary for some
ligands binding to RXRα. Instead, in the case of N-6, the π-π
stacking interactions and hydrophobic interactions contribute
to the binding of N-6 to RXRα (Fig. 4C–E). N-6, CF31, and
Danthron are RXRα antagonists while Magnolol and Bige-
lovin are RXRα agonists. Both as antagonist of RXRα,
Danthron and N-6 might use different antagonistic mecha-
nisms. In contrast with stabilization of RXRα tetramer by
Danthron (Zhang et al., 2011c), N-6 might induce the con-
formational changes of RXRα dimer to inhibit its homodimer
transactivation (Figs. 2A and 4F). The different mechanisms
should be due to the distinct spatial structures and binding
modes of Danthron and N-6 that lead to different confor-
mational changes of RXRα. It will be of great interests to
study how distinct RXRα conformational changes induced by
these compounds without acidic group deﬁne their regulation
properties and mechanisms of RXRα activities.
Crystal structure of TR3 indicates that it lacks a normal
LBP (Wang et al., 2003). Although many compounds have
been identiﬁed to bind to TR3 (Lee et al., 2011), the con-
troversy of the cognate ligands of TR3 still exists. Thus, it
might be difﬁcult to design and apply strategy to regulate
TR3 physiopathological functions by small molecules directly
targeting TR3. An alternative approach is to use small
molecules to regulate TR3 functions indirectly by targeting
TR3 interacting proteins. Our study provides an example to
show the feasibility of this approach. In the absence of
binding to its cognate DNA elements, the transactivation of
TR3 associated with RXRα was able to be inhibited by N-6
through binding to RXRα (Fig. 3D). The conformational
change of RXRα induced by N-6 binding may enhance
RXRα recruiting co-repressors that would prevent co-acti-
vator recruitment of TR3 due to steric hindrance, or may
affect the activating conformation of TR3, especially its AB
domain, in the RXRα/TR3 heterodimer. The activities of TR3
modulated by N-6 may not be limited to its transcriptional
activities. Besides regulating gene transcription, TR3 also
interacts with many proteins to exert its non-genomic func-
tions in the absence of DNA binding (Lin et al., 2004; Moll
et al., 2006). Therefore, our study also provides a potential
strategy to use small molecules to target RXRα to regulate
TR3 non-genomic functions.
The physiological functions of ligands often depend on
their abilities of inducing conformational changes of their
cognate nuclear receptors followed by the changes of
interactions of nuclear receptors with other proteins. The
conformational change of tRXRα induced by N-6 disrupted
the interaction of tRXRα and p85α, leading to the inhibition of
TNFα-induced AKT activation (Fig. 5). However, in the case
of the interaction of RXRα and TR3, N-6 did not disrupt the
interaction but deﬁnitely changed the interaction manner,
leading to the inhibition of TR3 transactivation (Fig. 3).
Therefore, there are two modes for N-6 to regulate RXRα
interactions with other proteins. One is to regulate the
interaction strength, and the other one is to regulate the
interaction manner. The regulation mode of RXRα interaction
by N-6 should be determined by the interacting domains of
both RXRα and its interacting partners such as TR3 as well
as other interacting proteins in the RXRα-formed complex
such as co-activators and co-repressors in the RXRα/TR3
complex.
TNFα is a double-edged sword in tumor development
(Balkwill, 2009; Waters et al., 2013). It stimulates caspase8-
dependent apoptosis, and/or promotes survival mainly
through PI3K/AKT and NFκB pathways (Mocellin and Nitti,
2008; Balkwill, 2009; Waters et al., 2013). In most cases,
TNFα acts as a promoter rather than a killer in tumor cells
and tissues because of its abnormally elevated survival
functions (Mocellin and Nitti, 2008; Balkwill, 2009; Waters
et al., 2013). To take the advantage of TNFα’s apoptotic
functions in cancer treatment, its survival signals in cancer
cells need to be blocked. Our previous discovery provides a
potential target—tRXRα for small molecules targeting to
inhibit TNFα survival signals. Our current study presents
several lines of evidence that N-6 could target tRXRα to
convert TNFα signal from survival to death. First, N-6
strongly inhibited TNFα-induced AKT activation in cancer
cells (Fig. 5A and 5B). Second, N-6 and TNFα synergistically
induced caspase-8 activation and cancer cell apoptosis
(Fig. 6B–E). Third, the functions of N-6 on AKT inhibition and
apoptosis-induction with TNFα were dependent on RXRα/
tRXRα expression (Figs. 5B and 6E). Forth, N-6 inhibited the
interactions of tRXRα and p85α (Fig. 5C and 5D).
Taken together, our results identify a new RXRα antago-
nist with abilities to modulate TR3 functions indirectly by
binding to RXRα and to convert TNFα signal to induce
cancer cell apoptosis by targeting tRXRα.
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NSC-640358 was provided by the NCI/DTP Open Chemical
Repository and the DTP website address is http://dtp.cancer.gov.
Fermentas TurboFect in vitro transfection reagent, DharmaFECT 1
transfection reagent, Gaussia-Dura Luciferase Glow Assay Kit, goat
anti-rabbit and anti-mouse secondary antibody conjugated to
horseradish peroxidase from Thermo Fisher Scientiﬁc, Inc. (Wal-
tham, MA, USA); CD3254, UVI3003, anti-AKT1 (C-20, sc-1618),
anti-c-Myc (9E10, sc-40), anti-RXR (ΔN197, sc-774), anti-RXR
(D20, sc-553) from Santa Cruz Biotechnology (Santa Cruz, CA,
USA); anti-caspase-8 (1C12, #9746), anti-phospho-AKT (Ser473)
(D9E, 4060) from Cell Signaling Technology (Boston, MA, USA);
anti-poly (ADP-ribose) polymerase (PARP, 556494) from BD Bio-
sciences (San Diego, CA, USA); 9-cis-Retinoic Acid, anti-β-actin
antibody from Sigma (St. Louis, MO, USA); anti-PI3 kinase (p85α,
04-403), polyvinylidene diﬂuoride membranes from Millipore (Biller-
ica, MA, USA); TR-FRET Retinoic X Receptor alpha coactivator
assay kit (PV4797) from invitrogen (Carlsbad, CA, USA); rhTNF-α
(Tumor Necrosis Factor-α, Human, Recombinant) from Promega
(Beijing, China); enhanced chemiluminescence reagents from GE
Healthcare (Buckinghamshire, UK) and a cocktail of proteinase
inhibitors from Roche (Meylan, France); [3H]9-cis-Retinoic Acid from
PerkinElmer (Boston, MA, USA) were used in this study.
Cell culture and transient transfection
MCF-7 breast cancer cells, HCT116 colon cancer cells, HeLa cervix
cancer cells, H292 lung cancer cells, A549 lung cancer cells,
HEK293T cells, and CV-1 cells were obtained from American Type
Culture Collection (ATCC) and cultured in Dulbecco’s modiﬁed
Eagle’s medium containing 10% fetal bovine serum (FBS). All cell
lines used were passaged in our lab for fewer than 4 months after
resuscitation, and were used at the ﬁfth through tenth passage in
culture for this study. Transient transfection was performed using
TurboFect according to the instructions of the manufacturer in reg-
ular growth medium.
Fluorescence ligand binding assay
A dilution series of the compound N-6 in potassium phosphate buffer
(10 mmol/L, pH 7.50) was made on a 96-well polypropylene plate,
which was subsequently transferred onto a 96-well, half-area UV-
transparent quartz plate in duplicate, 50 μL/well. The stock solution
of the protein RXRα ligand binding domain was diluted into potas-
sium phosphate buffer to reach 0.60 μmol/L, which was immediately
transferred onto the quartz plate, 10 μL/well. The ﬂuorescent inten-
sities of the compound were acquired on a FlexStation 3 Microplate
Reader (Molecular Devices, Sunnyvale, CA). In order to minimize
the interference from the intrinsic ﬂuorescence of Trp residues, time-
resolved ﬂuorescence mode was used. Data analyses were per-
formed with GraphPad Prism 5.0d.
Mammalian one-hybrid assays
MCF-7 cells seeded in 48-well plates were transiently cotransfected
with the luciferase reporter plasmid pG5-Gaussia (40 ng), pBind-
receptors (40 ng), and β-Gal plasmid (2 ng). Twenty-four hours after
transfection, the medium was replaced by medium containing a
respective ligand and/or a testing compound. After 18 h, the medium
was collected and assayed by using Gaussia-Dura Luciferase Glow
Assay Kit (Pierce). Cells were washed, lysed and assayed for β-Gal
activity. Transfection efﬁciency was normalized to β-Gal activity.
Mammalian two-hybrid assays
MCF-7 cells seeded in 48-well plates were transiently cotransfected
with the luciferase reporter plasmid pG5-Gaussia (40 ng), pBind-
TR3-LBD (40 ng), pACT-RXRα and β-Gal plasmid (2 ng). Twenty-
four hours after transfection, the medium was replaced by medium
containing a respective ligand and/or a testing compound. After 18 h,
the medium was collected and assayed by using Gaussia-Dura
Luciferase Glow Assay Kit (Pierce). Cells were washed, lysed, and
assayed for β-Gal activity. Transfection efﬁciency was normalized to
β-Gal activity.
CAT assays for NR response elements
CV-1 cells seeded in 24-well plates were transiently cotransfected
with one of the luciferase reporter plasmids pBLCAT2-TREpal
(100 ng)/pBLCAT2-βRARE (100 ng)/pBLCAT2-NurRE (100 ng), one
or two NR expressing plasmids pCMV-Myc-RXRα (20 ng)/pCMV-
Myc-RARγ (20 ng)/pCMV-Myc-TR3 (20 ng), and pCMV-Myc-β-Gal
(5 ng) as internal reference. Twenty-four hours after transfection, the
medium was replaced by medium containing a respective ligand
and/or a testing compound. After 18 h, cells were harvested and
assayed for CAT and β-Gal activity. Transfection efﬁciency was
normalized to β-Gal activity.
TR-FRET RXRα coactivator assays
Invitrogen’s LanthsScreen time-resolved ﬂuorescence resonance
energy transfer (TR-FRET) assay was used. Retinoic X Receptor
alpha coactivator assay was conducted according to manufacture’s
protocol. The TR-FRET ratio was calculated by dividing the emission
signal at 520 nm by the emission signal at 495 nm.
SPR measurements
The binding kinetics between RXRα-LBD and N-6 was analyzed at
25°C on a BIAcore T200 machine with CM5 chips (GE Healthcare).
PBSP was used for all measurements. A blank channel was used as
negative control. About 10,000 response units of RXRα-LBD were
immobilized on the chip. When the data collection was ﬁnished in
each cycle, the sensor surface was regenerated with Glycine-HCl
2.5. A series of concentrations of N-6 ranging from 3.125 to
100 μmol/L were applied for experiment. Sensograms were ﬁt
globally with BIAcore T200 analysis using 1:1 Langumuir binding
mode.
siRNA and transfections
siRNAs against RXRα (SASI-HS01-00097639) and control siRNA
(SIC001) used were from Sigma. Cells were transfected with 5 μL
aliquot of 20 μmol/L siRNA/well in six-well plates using
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DharmaFECT 1 transfection reagent, according to the manufac-
turer’s recommendations.
Western blotting
Cell lysates were prepared by lysing cells with lysis buffer containing
25 mmol/L Tris, 150 mmol/L NaCl, 1 mmol/L EDTA, 1% NP-40, 5%
glycerol, pH 7.4 with a cocktail of proteinase inhibitors on ice for
30 min. Equal amounts of the lysates were electrophoresed on an
SDS-PAGE gel (8% or 12%) and transferred onto polyvinylidene
diﬂuoride membranes, which were then blocked with 5% nonfat milk
in TBST [50 mmol/L Tris-HCl (pH 7.4), 150 mmol/L NaCl, and 0.1%
Tween 20] for 1 h, incubated with various primary antibodies over-
night at 4°C and incubated with secondary antibodies for 1 h at room
temperature. Immunoreactive products were detected by chemilu-
minescence with an enhanced chemiluminescence system.
Co-immunoprecipitation (Co-IP) assays
For Co-IP assay, cells grown in 10-cm dishes were transfected with
various plasmids for 24 h. After transfection and treatments, cells
were harvested. Cell lysates were incubated with the appropriate
antibody for 2 h, and subsequently incubated with protein
A-Sepharose beads for 2 h. The protein-antibody complexes
recovered on beads were subjected to Western blotting using
appropriate antibodies after separation by SDS-polyacrylamide gel
electrophoresis.
Ligand-binding competition assays
The His-tagged human RXRα-LBD (223–462) was incubated in
tubes with unlabeled 9-cis-RA or different concentrations of com-
pounds in 200 μL binding buffer [0.15 mol/L KCl, 10 mmol/L Tris·HCl
(pH 7.4), 8% glycerol, 0.5% CHAPS] at 4°C for 1 h. [3H]-9-cis-RA
was added to the tubes to a ﬁnal concentration of 7.5 nmol/L and
ﬁnal volume of 300 μL then incubated overnight at 4°C. The RXRα-
LBD was then captured by nickel-coated beads. Bound [3H]-9-cis-
RA was quantitated by liquid scintillation counting.
Colony formation assay
HeLa cells were seeded in 6-well plate (500 cells/well) for 3 days,
and were treated with N-6 (5 μmol/L) and TNFα (10 ng/mL) alone or
in combination in 1% serum medium for 3 days. Cells were ﬁxed with
4% paraformaldehyde. Colonies were stained with 0.1% crystal
violet and counted.
Tunel staining
MCF-7 cells were ﬁxed in 4% paraformaldehyde and permeabilized
with 1% Triton X-100 in phosphate-buffered saline. Cells were
blocked using 3% H2O2 (80 mL methanol + 10 mL ddH2O + 10 mL
30% H2O2) for 10 min. TUNEL reaction mixture was obtained by
adding terminal deoxynucleotidyl transferase and Biotin-11-dUTP.
Each sample was then incubated with TUNEL reaction mixture in a
humidiﬁed chamber at 37°C in dark for 60 min, and then labeled with
Streptavidin-HRP. DAB staining was used for coloration. Nucleus
was stained by hematoxylin.
Virtual ligand screening
Virtual ligand screening (VLS) of approximate 200,000 compound
library of the Developmental Therapeutics Program (DTP) NCI/NIH
(http://dtp.nci.nih.gov) was performed using Q-MOL molecular
modeling package (Q-MOL L.L.C., San Diego, CA, USA; www.q-
mol.com) (Shiryaev et al., 2011; Remacle et al., 2012; Shiryaev
et al., 2012). The Optimized Potential for Liquid Simulations (OPLS)
all atom force ﬁeld (Jorgensen et al., 1996) is uniformly utilized within
the Q-MOL program. The ligand docking simulations were con-
ducted using the RXRα crystal structure coordinates from 3FUG
PDB. The docking site was prepared as an area encompassing both
the ligand binding pocket and the peptide cofactor binding site. The
protein molecule preparation included adding of hydrogen atoms
and the assignment of the standard OPLS atom types. To increase
the speed of calculations and to incorporate implicitly the ﬂexibility of
RXR, the protein molecule was treated as a set of grid-based
potentials accounting for the relevant protein-ligand interactions. The
ligands were docked into the grid-based potentials using the Monte
Carlo simulation in the internal coordinate space as implemented in
the Q-MOL program. The preparation of each ligand for docking
simulation initially included an automatic OPLS atom type assign-
ment and conversion of the 2D sketch-like models (input as the MDL
MOL format) into the 3D molecular models. The full-atom ligand
structure was then minimized using the Q-MOL small molecule
minimization protocol. The protocol combines minimization in both
internal and Cartesian coordinates to properly optimize the rotable
bonds of a small molecule. In the course of VLS, the compounds
were minimally ﬁltered by applying lower molecular mass cut-off of
220 Da, a polyphenols sub-structure ﬁlter, and a ﬁlter detecting
chlorine atoms attached to aliphatic carbons. Because of the
stochastic nature of the Q-MOL docking protocol, each ligand was
docked at least three times. The best energy conformers with the
lowest binding energy were then selected. To differentiate between
the true and false binders, Q-MOL VLS uses a proprietary protein-
ligand binding energy evaluation function. This function is based on
the re-parameterized OPLS force ﬁeld, and, in addition to the pro-
tein-ligand interactions, it accounts for the internal energy change of
the docked ligand. Upon completion of VLS, the hits were ranked by
relative binding energy, and the best (lowest) energy hits were then
selected. The selected hits were visually inspected and the highly
symmetric or heavily halogenated ligands and the high molecular
weight compounds were discarded and not analyzed further. Out of
100 predicted hits, only 11 were selected and ordered from NCI DTP
for in vitro testing.
Modeling of protein-ligand complex
The structure of RXRα was retrieved from crystal complex
LG100754-RXRα (PDB entry: 3a9e). Glide was used to study the
interaction of ligand-RXRα complex (LG100754 and N-6) in the suite
of Schrodinger with default docking parameter settings. The inter-
action image was produced by the Pymol software.
Statistical analysis
Data were expressed as mean ± SD. Each assay was repeated in
triplicate in three independent experiments. Statistical signiﬁcance of
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differences between groups was analyzed by using Student’s t test.
P < 0.05 was considered signiﬁcant.
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